Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study

Table 2 Treatment and efficacies of first-line chemoradiotherapy

	Overall		Platinum group		non-Platinum group		P-value
	n = 320		n = 119		n = 201		P-value
	n	%	n	%	n	%
Platinum
CDDP	189	59.1	68	57.1	121	60.2	0.21
CBDCA	129	40.3	49	41.2	80	39.8
Unknown	2	0.6	2	1.7	0	0
Radiation dose
≥ 60 Gy	271	84.7	96	80.7	175	87.1	0.10
< 60 Gy	47	14.7	23	19.3	24	11.9	0.10
Unknown	2	0.6	0	0	2	1.0
Response to chemoradiotherapy
ORR (%)		67.5		65.5		68.7	0.62
Duration from the start of first-line therapy to the start of second-line therapy
Median (range), (months)	8.6	(0.5–46.2)	6.6	(0.5–46.2)	8.7	(0.5–38.0)	< 0.01

CDDP cisplatin, CDBCA carboplatin, ORR objective response rate, Gy, gray
P values were calculated using the Fisher’s exact test for categorical variables and with Mann–Whitney U test for continuous variables

ISSN: 1471-2407